NEW YORK (GenomeWeb) – Roche said late on Tuesday that Pathology Inc. has become a Roche Molecular Center of Excellence for the next five years.
With the designation, Pathology's molecular diagnostic laboratory will be able to offer molecular technologies from Roche, such as the US Food and Drug Administration-approved cobas HPV test, to physicians and patients. The test helps clinicians assess a patient's risk of cervical cancer based on the presence of clinically relevant high-risk HPV DNA.
Headquartered in Torrance, Calif., Pathology is a full-service independent women's health laboratory. It now becomes one of 35 labs in the US to be designated a Roche Molecular Center of Excellence, a program that was created in 2002 to enable non-competing labs the ability "to collaborate and capitalize on scientific knowledge in molecular testing, and, in turn, help accelerate the advancement of new test methods and technology," Roche said in a statement.
Among the other labs in the program are med fusion and the Cedars-Sinai Medical Center.